A comprehensive view of Eisai Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
European Medicines Agency delays decision on Biogen and Eisai's Alzheimer's drug lecanemab due to procedural implications from an EU court ruling; the delay is unrelated to the marketing authorization application submitted for lecanemab
Published:
March 26, 2024
by Zack's Commentary
|
Eisai obtains marketing authorization from Japan's Ministry of Health for injectable form of antiepileptic drug Fycompa; the new formulation provides an alternative therapy for patients unable to take the drug orally.
Published:
January 23, 2024
by PharmaBiz
|
China approves Eisai's Leqembi injectable to treat minor dementia and cognitive dysfunction triggered by Alzheimer’s; China also approves Gilead's Descovy tablet for pre-exposure prophylaxis to lower the risk of HIV infection
Published:
January 16, 2024
by ForeignAffairs.co.nz
|
Eisai and Biogen's Alzheimer's treatment, Leqembi, gets approval from Japan's health ministry, making Japan the second country after the US to permit its use; the drug helps reduce the progression of mild cognitive impairment and mild dementia
Published:
September 27, 2023
by Business Day
|
Merck, Eisai report immunotherapy Keytruda and the cancer drug Lenvima combined therapy fails in lung cancer trials
Published:
September 25, 2023
by SeeNews Pharmaceuticals
|
Ask us about our Health Care Sector market view